Following great progress on the pathogenesis of lupus nephritis (LN) and publication of many high quality (prospective,randomized,multicenter) clinical trials of glucocorticoids-plus-immunosuppressive interventions,the American College of Rheumatology (ACR),European League Against Rheumatism (EULAR)/European Renal Association-European Dialysis and Transplant Association (ERA-EDTA),and Kidney Disease:Improving Global Outcomes (KDIGO) published or renewed in succession in 2012 special guidelines or recommendations for screening,casedefinition,treatment and management of LN.The paper introduces the key contents to provide reference for the clinical practice.